Prime Medicine, Inc. Increase (Decrease) in Accounts Payable
Prime Medicine, Inc. (PRME) reported Increase (Decrease) in Accounts Payable of -$2.97 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06
- Prime Medicine, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$6.52M.
- Prime Medicine, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $3.55M, a 88.54% increase year-over-year.
- Prime Medicine, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$581.00K, a 123.62% decline year-over-year.
- Prime Medicine, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $3.04M, a 100.79% increase year-over-year.
- Prime Medicine, Inc. increase (decrease) in accounts payable for fiscal 2025 was $996.00K.
- Prime Medicine, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$5.26M, a 157.52% decline from fiscal 2023.
- Prime Medicine, Inc. increase (decrease) in accounts payable for fiscal 2023 was $9.14M, a 271.85% increase from fiscal 2022.
- Prime Medicine, Inc. increase (decrease) in accounts payable for fiscal 2022 was $2.46M, a 107.43% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$6.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$2.97M 10-Q · filed 2026-08-06 | -$3.55M derived: sum of 3 quarters · filed 2026-08-06 | -$509.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $3.55M 10-Q · filed 2026-05-07 | $2.97M derived: sum of 2 quarters · filed 2026-05-07 | $6.01M derived: sum of 3 quarters · filed 2026-05-07 | $2.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$581.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $2.46M derived: sum of 2 quarters · filed 2026-03-03 | -$888.00K derived: sum of 3 quarters · filed 2026-08-06 | $996.00K 10-K · filed 2026-03-03 |
| 2025-09-30 | $3.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$307.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.58M 10-Q · filed 2025-11-07 | $4.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$3.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.46M 10-Q · filed 2026-08-06 | $999.00K derived: sum of 3 quarters · filed 2026-08-06 | $2.51M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.88M 10-Q · filed 2026-05-07 | $4.34M derived: sum of 2 quarters · filed 2026-05-07 | $5.86M derived: sum of 3 quarters · filed 2026-05-07 | $2.51M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $3.97M derived: sum of 2 quarters · filed 2026-03-03 | $623.00K derived: sum of 3 quarters · filed 2026-03-03 | -$5.26M 10-K · filed 2026-03-03 |
| 2024-09-30 | $1.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$1.84M derived: sum of 2 quarters · filed 2025-11-07 | -$7.72M 10-Q · filed 2025-11-07 | -$5.44M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | -$3.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$9.23M 10-Q · filed 2025-08-07 | -$6.95M derived: sum of 3 quarters · filed 2025-08-07 | -$1.19M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$5.88M 10-Q · filed 2025-05-08 | -$3.60M derived: sum of 2 quarters · filed 2025-05-08 | $2.16M derived: sum of 3 quarters · filed 2025-05-08 | $3.76M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $8.04M derived: sum of 2 quarters · filed 2025-02-28 | $9.64M derived: sum of 3 quarters · filed 2025-02-28 | $9.14M 10-K · filed 2025-02-28 |
| 2023-09-30 | $5.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $7.37M derived: sum of 2 quarters · filed 2024-11-12 | $6.86M 10-Q · filed 2024-11-12 | $7.29M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.10M 10-Q · filed 2024-08-08 | $1.53M derived: sum of 3 quarters · filed 2024-08-08 | $1.13M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$504.00K 10-Q · filed 2024-05-10 | -$73.00K derived: sum of 2 quarters · filed 2024-05-10 | -$474.00K derived: sum of 3 quarters · filed 2024-05-10 | $907.00K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $431.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $30.00K derived: sum of 2 quarters · filed 2024-03-01 | $1.41M derived: sum of 3 quarters · filed 2024-03-01 | $2.46M 10-K · filed 2024-03-01 |
| 2022-09-30 | -$401.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $980.00K derived: sum of 2 quarters · filed 2023-11-03 | $2.03M 10-Q · filed 2023-11-03 | $2.11M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $2.43M 10-Q · filed 2023-08-07 | $2.51M derived: sum of 3 quarters · filed 2023-08-07 | |
| 2022-03-31 | $1.05M 10-Q · filed 2023-05-11 | $1.13M derived: sum of 2 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $80.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $1.19M 10-K · filed 2023-03-09 | ||
| 2021-09-30 | $1.10M 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $250.00K 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |